• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Kezar Life Sciences Inc (NQ: KZR )

    0.6311 -0.0252 (-3.84%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 501,715
    Open 0.6509
    Bid (Size) 0.6310 (1)
    Ask (Size) 0.6499 (17)
    Prev. Close 0.6563
    Today's Range 0.6311 - 0.6600
    52wk Range 0.6318 - 2.605
    Shares Outstanding 72,407,215
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
    From Kezar Life Sciences, Inc.
    Via Business Wire

    Performance

    YTD
    -33.57%
    -33.57%
    1 Month
    -11.36%
    -11.36%
    3 Month
    -29.40%
    -29.40%
    6 Month
    -26.72%
    -26.72%
    1 Year
    -73.37%
    -73.37%

    More News

    Read More
    KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024
    Via InvestorPlace
    Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Analyst Expectations for Kezar Life Sciences's Future
    Via Benzinga
    Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    From Kezar Life Sciences, Inc.
    Via Business Wire
    From Pennies to Fortunes: 3 Stocks Set to Make Millionaires
    Via InvestorPlace
    Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
    Via InvestorPlace
    KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
    Via InvestorPlace
    Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
    Via Talk Markets
    Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
    From Kezar Life Sciences, Inc.
    Via Business Wire
    3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
    Via InvestorPlace
    3 Penny Stocks Poised for an Unbelievable 1,000% Jump
    Via InvestorPlace
    As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
    Via InvestorPlace
    Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    From Kezar Life Sciences, Inc.
    Via Business Wire
    10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
    Via ACCESSWIRE
    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.